Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Recruiting

Phase 1

AMG 513Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Sponsor:

Amgen

Code:

NCT06585462

Conditions

Cardiometabolic Disease

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

AMG 513

Placebo

AMG 513

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-20. This information was provided to ClinicalTrials.gov by Amgen on 2026-06-22.